Navigation Links
Denver Spine Physicians Begin Enrollment in United States Stem Cell Therapy Study

GREENWOOD VILLAGE, Colo., Dec. 13, 2011 /PRNewswire-iReach/ -- DenverSpine today announced that it has enrolled its first patient in a nationwide FDA- cleared adult stem cell study testing novel treatment for chronic low back pain. The study will test the use of Mesenchymal Precursor Cells (MPCs) – adult stem cells derived from bone marrow that will be directly injected into the lumbar disc.  The minimally invasive procedure may offer an alternative to back surgery for eligible patients with chronic pain from degenerative discs.

An estimated 30 million people in the United States suffer from back pain. Degenerative disc disease is the most common cause of low-back pain, which develops with the gradual loss of a material called proteoglycan, which cushions the bones of the spine and enables normal motion.

Most patients with low-back pain respond to physical therapy and medications, but in advanced cases, artificial disc replacement or spinal fusion -- removal of the degenerated discs and the fusion of the bones of the spine -- is necessary. However, these surgeries often are not entirely effective.

J. Scott Bainbridge, M.D. is the lead researcher providing spinal injections for the study, and Gary Ghiselli, M.D. is the principal investigator. Both doctors agree on the critical need for a minimally invasive solution to a common, debilitating condition.

"The study is the first of its kind in the United States and we are very excited by the potential of these adult stem cells to provide a novel therapeutic approach," said Dr. Bainbridge.

Researchers will enroll approximately 100 study participants. About 10 – 20 participants will be enrolled at the Denver site and the rest at 11 other medical centers throughout the United States.  The trial is scheduled to last for three years.

DenverSpine is enrolling study participants suffering from moderate low-back pain for a minimum of six months and whose condition has not responded to other, conventional treatments.

Once enrolled, patients are randomly assigned to one of four treatment groups:

  • One group will receive a high dose of MPCs, plus hyaluronic acid, a substance that facilitates the localization and retention of the stem cells;
  • A second group will receive a lower dose of MPCs, plus the hyaluronic acid;
  • A third group will receive the hyaluronic acid alone;
  • A fourth group will receive only the saline solution.

Patients will receive a single injection of their assigned test agent directly into the center of the target discs within their spine and will be monitored for safety.  Patients will also be monitored using imaging to identify any changes in their disease condition or disease progression. Use of pain medications, self-reports of pain, subsequent surgical interventions and assessments of disability, quality of life, productivity and activity will be evaluated. Repair of the disc and reduction of chronic back pain will be assessed in each patient. 

Promising results have been observed in prior research using animal models when stem cells were investigated for the repair of damaged spine discs.The cells were well tolerated in these study animals.

This study is sponsored by Mesoblast Limited,a world leader in the development of biologic products for the broad field of regenerative medicine.  Mesoblast has the worldwide exclusive rights to a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs).  The MPCs are derived from young adult donors' bone marrow and are immune tolerant.

For more information, go to

For additional information on the clinical trial, please see the listing on study identifier number NCT01290367

Media Contact: Jami Henriksen, DenverSpine, 303-783-1300 ext 158,

News distributed by PR Newswire iReach:

SOURCE DenverSpine
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cheyenne Regional Medical Center Announces New Air Ambulance Service Partnership with HealthONEs AirLife Denver
2. Colorado Association of School Nurses Unites Denver Community to Combat Low Meningitis Vaccination Rates Among Preteens and Teens
3. Denver School Nurses Unite Community in the Fight against Meningitis, a Potentially Deadly Disease
4. Denver Zoo Orangutan Breathes Easier With eFlow Technology From PARI
5. Invision Sally Jobe Introduces New Breast Cancer Screening Technology to Denver
6. Denver-Ft. Collins Ophthalmologist First in Colorado to Implant nanoFLEX Lens
7. American Lung Association in Colorados Faces of Influenza Initiative Rolls Up its Sleeves to Kick Off Flu Season in Denver
8. CSC Announces Billing Contract with Denver Endocrinology Diabetes and Metabolism
9. SpineMark Partners With Regional Spine Leaders to Launch Its First Multisite Spine Research Organizations in Los Angeles, Denver
10. RSB Spine, LLC, Announces European Patent Allowance
11. Thompson MIS Wins a Best New Technology in Spine Care 2011 Award
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 /PRNewswire/ ... --> Juntendo universitetssjukhus ser potential att ... av magnetresonansbilder (MR-bilder) för patienter med ... tecknat ett forskningsavtal med SyntheticMR AB för ... kliniska forskningsprojekt på sjukhuset. Med SyMRI kan ...
(Date:11/26/2015)... , November 26, 2015 ... --> adds "Global Repaglinide ... "Investigation Report on China Repaglinide Market, ... forecasts data and information to its ... . --> ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... ... The holiday season is jam-packed with family dinners, parties ... is of the utmost importance. Whether you are cooking at home for the ... try this holiday season. , Turkey Croquettes ,     Ingredients: , ...
(Date:11/25/2015)... ... November 25, 2015 , ... Dr. John Pierce, Medical Director at the ... loss treatment with the Capillus272™ Pro laser therapy cap. FDA cleared for safety and ... hair, without the need for surgery, prescription pills, or topical foams. , “Capillus272™ ...
(Date:11/25/2015)... , ... November 25, 2015 , ... According to an ... robot is being more and more widely heralded as a breakthrough for performing hernia ... method has over traditional laparoscopic surgery is that it can greatly reduce the pain ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... for physicians and athletic programs, launches new Wimbledon Athletics Facebook page ... testing young athletes for unsuspected cardiac abnormalities. About 2,000 people under the age ...
(Date:11/25/2015)... ... November 25, 2015 , ... SCOTTSDALE, ... facial plastic surgeon specializing in both surgical and non-surgical treatments, announced the expansion ... at Hobgood Facial Plastic Surgery. , Highly trained and nationally recognized for ...
Breaking Medicine News(10 mins):